Back to results
US 11,077,210 B2Granted
Near-infrared fluorescent contrast bioimaging agents and methods of use thereof
AssigneesBeth Israel Deaconess Medical Center, Inc., Georgia State University Research Foundation, Inc.
InventorsJohn V. Frangioni, Hak Soo Choi, Maged M. Henary
Life of this patent
Estimating the term…
Abstract
The instant invention provides near-infrared fluorescent biological contrast agents and methods of using them.
Claims7
A method of imaging tissue, lumens, or cells, the method comprising:
- (a) intravenously administering an imaging composition to an organism comprising the tissue, lumen, or cells wherein the imaging composition consists essentially of an imaging agent, wherein intravenously administering the imaging composition comprises contacting the tissue, lumen or cells with the imaging agent, wherein the imaging agent is ESS 61:
- (b) irradiating the tissue, lumen, or cells at a wavelength absorbed by the imaging agent;
- (c) and detecting a signal from the imaging agent, thereby imaging the tissue, lumen, or cells.
A method of imaging neuroendocrine tumor cells, the method comprising:
- (a) intravenously administering an imaging composition to an organism comprising the neuroendocrine tumor cells, wherein the imaging composition consists essentially of an imaging agent, and wherein the intravenously administering comprises contacting the neuroendocrine tumor cells with the imaging agent, wherein the imaging agent is ESS 61:
- (b) irradiating the neuroendocrine tumor cells at a wavelength absorbed by the imaging agent;
- (c) and detecting a signal from the imaging agent, thereby imaging the neuroendocrine tumor cells.
A method of imaging breast cancer cells, the method comprising:
- (a) intravenously administering an imaging agent to an organism comprising the breast cancer cells, wherein the imaging composition consists essentially of an imaging agent, and wherein the intravenously administering comprises contacting the breast cancer cells with the imaging agent, wherein the imaging agent is ESS 61:
- (b) irradiating the neuroendocrine tumor cells at a wavelength absorbed by the imaging agent;
- (c) and detecting a signal from the imaging agent, thereby imaging the breast cancer cells.
Dependencies are inferred from the claim text.